Chikungunya Vaccine Immunogenic and Safe in a Phase I Trial

In an open-label trial among adults, a viruslike particle–based chikungunya vaccine induced durable neutralizing antibodies and was well tolerated.

Chikungunya virus, endemic in Africa and Asia and transmitted via the bites of infected mosquitoes, has now spread into the Americas. No vaccine or specific therapy is currently available. A viruslike particle (VLP)-based chikungunya vaccine has been shown to elicit neutralizing antibodies and protect nonhuman primates from infection and illness. To assess immunogenicity and safety in humans, investigators conducted a phase I trial of a VLP chikungunya vaccine in healthy adults.

The vaccine was administered intramuscularly at weeks 0, 4, and 20 in three dosage groups (10 µg, n=5; 20 µg, n=10; and 20 µg, n=10). Twenty-three of the 25 participants received all three doses. Neutralizing antibodies were present in all participants 4 weeks after …

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Chikungunya Vaccine Immunogenic and Safe in a Phase I Trial

Topics

Reviewing Author